Progenika Biopharma
Contact information
Progenika Biopharma, SA
Sergio Escorza, Director de Alianzas Estratégicas Internacionales
Parque Tecnológico de Bizkaia
Derio
Bizkaia
944064525
944064526
Areas of activities
- A. Health Biotechnology
- Areas of activity
- Biodrugs
- In vitro diagnostics
- Therapeutic areas
- Analgesia & Pain
- Dermatology
- Cardiovascular diseases and circulatory system
- Genetic and rare diseases
- Infectious diseases
- Inflammatory diseases
- Immunology
- Ophtalmology and optometry
- Oncology
- Blood and lymphatic system
- Digestive system and hepatology
- Kidney and genitourinary system
- Central nervous system
- Metabolic disorders / Endocrinology
- B. Agrifood Biotechnology
- Agriculture / veterinary / environmental
- Other enhancement techniques (molecular marker..)
- Animal health / Veterinary
- C. Industrial Biotechnology
- Manufacture of biotech equipment
- D. Services
- R&D services
- Bioinformatics
- Biotechnolgy kits
- Genomics
- Metabolomics
- Proteomics
- Professional services
- Consultancy
Progenika´s mission is to improve healthcare through the development, validation and commercialization of products that allow personalization of treatment for complex diseases: in vitro tests for their prevention, diagnosis and prognosis; prediction of response to drugs; and monitoring of the effectiveness of biologic therapies.
Products and services
Areas of expertise and interest for Progenika Group companies include:
- Genotyping: Testing based on SNPs is applicable to a broad spectrum of studies, such as the identification of diseases and etiological research, gene association, mutational analyses, or associations between disease and gain/loss of chromosomal regions.
- Massive sequencing: de novo and re-sequencing technologies allow gathering significant gene functional information, offering a high capacity and data quality unattainable by traditional sequencing.
- Analyses of gene expression: our platforms make it possible to analyze simultaneously, in a quantitative and reproducible way, the expression levels of thousands of genes involved in a particular physiological process. Projects aimed at a restricted number of candidate genes and/or validation of expression markers is also possible.
- Non-coding RNA: the large number of genes regulated by microRNAs makes the analysis of this kind of molecules particularly interesting to identify those that are associated with different pathologies.
- Gene regulation: there are several technological options for the analysis of regulatory mechanisms, from massive sequencing studies applied to analysis of methylation to specific studies using microarrays.
- Production of solid and liquid microarrays and immunoassays: tests for the detection of proteomic and genomic biomarkers can be implemented in different formats, such as ELISAs, chips, or liquid arrays based on suspended microspheres or microparticles.tion sequencing; or solid array, liquid array and immunoassay development